Hyaluronic Acid Pills Arthritis Research

1. Meyer K, Palmer JW. The polysaccharide of the vitreous humor. J Biol Chem 1934; 107:629-634.

2. Weissmann B, Meyer K. The structure of hyalobiuronic acid and of hyaluronic acid from umbilical cord. J Am Chem Soc 1954; 76:1753-1757.

3. Noble PW. Hyaluronan and its catabolic products in tissue injury and repair. Mater Biol 2002; 21:25-29.

4. Horton MR, McKee CM, Bao C, Liao F, Farber JM, Hodge-DuFour J, Pure E, Oliver BL, Wright TM, Noble PW. Hyaluronan fragments synergize with interferon-g to induce the C-X-C chemokines Mig and interferon-inducible protein-10 in mouse macrophages. J Biol Chem 1998; 273:35088-35094.

5. McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, Bao C, Noble PW. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages: the role of HA size and CD44. J Clin Investig 1996; 98:2403-2413.

6. Noble PW, McKee CM, Horton MR. Induction of inflammatory gene expression by low-molecular-weight hyaluronan fragments in macrophages. Wenner-Gren Int Ser 1998; 72:219-225.

7. Kumar S, Kumar P, Ponting JM, Sattar A, Rooney P, Pye D, Hunter RD. Hyaluronic acid promotes and inhibits angiogenesis. NATO ASI Series, Series A. Life Sci 1992; 227:253-263.

8. Ghosh I, Bharadwaj A, Datta K. Reduction in the level of hyaluronan binding protein 1 (HABP1) is associated with loss of sperm motility. J Reprod Immunol 2002; 53:45-54.

9. Salamonsen LA, Shuster S, Stern R. Distribution of hyaluronan in human endometrium across the menstrual cycle implications for implantation and menstruation. Cell Tissue Res 2001; 306:335-340.

10. Zhuo L, Yoneda M, Zhao M, Yingsung W, Yoshida N, Kitagawa Y, Kawamura K, Suzuki T, Kimata K. Defect in SHAP-hyaluronan complex causes severe female infertility. A study by inactivation of the bikunin gene in mice. J Biol Chem 2001; 276:7693-7696.

11. Weiss C. Why viscoelasticity is important for the medical uses of hyaluronan and Hylans. Int Cong Ser 2000; 1196:89-103.

12. Turley EA, Noble PW, Bourguignon LYW. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277:4589-4592.

13. Lehmann R, Brint S, Stewart R, White GL Jr, McCarty G, Taylor R, Disbrow D, Defaller J. Clinical comparison of Provisc and Healon in cataract surgery. J Cataract Refract Surg 1995; 21:543-547.

14. Bresciani C, Lebuisson DA, Eveillard M, Grossiord JL, Drupt F, Montefiore G. Dynamic viscosity and corneal endothelial protection with Healonid, Healon GV, Provisc and Viscoat during phacoemulsification. J Fran D'Ophtal 1996; 19:39-50.

15. Uthman I, Raynauld JP, Haraoui B. Intra-articular therapy in osteoarthritis. Post Med J 2003; 79:449-453.

16. Prehm P. Hyaluronan in rheumatoid arthritis: a review. Int Cong Ser 2000; 1196:


17. Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Intra-articular injection of high molecular weight hyaluronan after arthrocentesis as treatment for rheumatoid knees with joint effusion. Rheum Int 2002; 22:151-154.

18. Ghosh P, Holbert C, Read R, Armstrong S. Hyaluronic acid (hyaluronan) in experimental osteoarthritis. J Rheum Suppl 1995; 43:155-157.

19. Tateda C, Nagamine H, Iwadate K, Nakamura T. Effects of sodium hyaluronate (ME3710) in rabbit models of osteoarthritis (OA) and periarthritis of the shoulder (PS). Yak Chir 1995; 23:833-841.

20. Maheu E, Ayral X, Dougados M. A hyaluronan preparation (500-730 kDa) in the treatment of osteoarthritis: a review of clinical trials with Hyalgan. Int J Clin Pract 2002; 56:804-813.

21. Barrett JP, Siviero P. Retrospective study of outcomes in Hyalgan-treated patients with osteoarthritis of the knee. Clin Drug Investig 2002; 22:87-97.

22. Goorman SD, Watanabe TK, Miller EH, Perry C. Functional outcome in knee osteoarthritis after treatment with hylan G-F 20: a prospective study. Arch Phys Med Rehabil 2000; 81:479-483.

23. Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, Zummer M. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995; 3:213-225.

24. Adams ME. An analysis of clinical studies of the use of crosslinked hyaluronan, hylan, in the treatment of osteoarthritis. J Rheum Suppl 1993; 39:16-18.

25. Laurent UB, Fraser JR, Engstrom-Laurent A, Reed RK, Dahl LB, Laurent TC. Catabolism of hyaluronan in the knee joint of the rabbit. Mater Biol 1992; 12:


26. Lebel L, Gabrielsson J, Laurent TC, Gerdin B. Kinetics of circulating hyaluronan in humans. Eur J Clin Investig 1994; 24:621-626.

27. Fraser JRE, Laurent TC. Turnover and metabolism of hyaluronan. Ciba Found Symp 1989; 143:41-59.

28. Fraser JRE, Laurent TC, Engstroem-Laurent A, Laurent UGB. Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Pharmacol Physiol 1984; 11:17-25.

van't Riet M, de Vos van Steenwijk Peggy J, Bonthuis F, Marquet Richard L, Steyerberg Ewout W, Jeekel J, Bonjer HJ. Prevention of adhesion to prosthetic mesh: comparison of different barriers using an incisional hernia model. Ann Surg 2003; 237:123-128.

Ozmen MM, Aslar AK, Terzi MC, Albayrak L, Berberoglu M. Prevention of adhesions by bioresorbable tissue barrier following laparoscopic intraabdominal mesh insertion. Surg Laparosc Endosc Percutan Tech 2002; 12:342-346. Ballore L, Orru F, Nicolini F, Contini SA, Galletti G, Gherli T. Experimental results of the use of hyaluronic acid based materials (CV Seprafilm and CV Sepracoat) in postoperative pericardial adhesions. Acta Biomed Ateneo Parmense 2000; 71:159-166.

Diamond MP. Reduction of de novo postsurgical adhesions by intraoperative precoating with Sepracoat (HAL-C) solution: a prospective, randomized, blinded, placebo-controlled multicenter study. The Sepracoat Adhesion Study Group. Fertil Steril 1998; 69:1067-1074.

Alponat A, Lakshminarasappa SR, Yavuz N, Goh PM. Prevention of adhesions by Seprafilm, an absorbable adhesion barrier: an incisional hernia model in rats. Am Surg 1997; 63:818-819.

Kling J. Genzyme's Seprafilm gets FDA marketing nod. Nat Biotech 1996; 14:572.

Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem 2002; 277:4585-4588.

Turley EA, Noble PW, Bourguignon LYW. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277:4589-4592.

Tammi MI, Day AJ, Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem 2002; 277:4581-4584.

Rein DT, Roehrig K, Schoendorf T, Lazar A, Fleisch M, Niederacher D, Bender HG, Dall P. Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumor progression and metastasis. J Can Res Clin Oncol 2003; 129:161-164.

Savani RC, Bagli DJ, Harrison RE, Turley EA. The role of hyaluronan-receptor interactions in wound repair. Bas Clin Derm 2000; 19:115-142.

Assmann V, Gillett CE, Poulsom R, Ryder K, Hart IR, Hanby AM. The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J Pathol 2001;


Ziebell MR, Zhao Z-G, Luo B, Luo Y, Turley EA, Prestwich GD. Peptides that mimic glycosaminoglycans: high-affinity ligands for a hyaluronan binding domain. Chem Biol 2001; 8:1081-1094.

Weigel JA, Raymond RC, Weigel PH. The hyaluronan receptor for endocytosis (HARE) is not CD44 or CD54 (ICAM-1). Biochem Biophy Res Commun 2002; 294:918-922.

Zhou B, Weigel JA, Fauss L, Weigel PH. Identification of the hyaluronan receptor for endocytosis (HARE). J Biol Chem 2000; 275:37733-37741. Banerji S, Ni J, Wang S-X, Clasper S, Su J, Tammi R, Jones M, Jackson DG. LYVE-1, a new homolog of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144:789-801.

Jackson DG. The lymphatics revisited. New perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med 2003; 13:1-7.

46. Prevo R, Banerji S, Ferguson DJP, Clasper S, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001; 276:19420-19430.

47. Toole BP, Wight TN, Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 2002; 277:4593-4596.

48. Ellis H. Medicolegal consequences of postoperative intra-abdominal adhesions. J R Soc Med 2001; 94:331-332.

49. Ellis H. The clinical significance of adhesions: focus on intestinal obstruction. Eur J Surg 1997:5-9.

50. Holmdahl L, Risberg B, Beck DE, Burns JW, Chegini N, diZerega GS, Ellis H. Adhesions: pathogenesis and prevention-panel discussion and summary. Eur J Surg 1997:56-62.

51. Ellis H, Moran BJ, Thompson JN, Parker MC, Wilson MS, Menzies D, McGuire A, Lower AM, Hawthorn RJ, O'Brien F, Buchan S, Crowe AM. Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study. Lancet 1999; 353:1476-1480.

52. Lower AM, Hawthorn RJ, Ellis H, O'Brien F, Buchan S, Crowe AM. The impact of adhesions on hospital readmissions over ten years after 8849 open gynaecological operations: an assessment from the Surgical and Clinical Adhesions Research Study. BJOG 2000; 107:855-862.

53. Parker MC, Ellis H, Moran BJ, Thompson JN, Wilson MS, Menzies D, McGuire A, Lower AM, Hawthorn RJ, O'Briena F, Buchan S, Crowe AM. Postoperative adhesions: ten-year follow-up of 12,584 patients undergoing lower abdominal surgery. Dis Colon Rectum 2001; 44:822-829.

54. Ellis H. The causes and prevention of intestinal adhesions. Br J Surg 1982; 69: 241-243.

55. Sjosten AC, Ellis H, Edelstam GA. Post-operative consequences of glove powder used pre-operatively in the vagina in the rabbit model. Hum Reprod 2000; 15: 1573-1577.

56. Ellis H. Experimental study of starch-induced intraperitoneal adhesions. Br J Surg 1991; 78:1020.

57. Kang N, Griffin D, Ellis H. The pathological effects of glove and condom dusting powders. J Appl Toxicol 1992; 12:443-449.

58. diZerega GS. Contemporary adhesion prevention. Fertil Steril 1994; 61:219-235.

59. diZerega GS. Biochemical events in peritoneal tissue repair. Eur J Surg 1997: 10-16.

60. DiZerega GS, Campeau JD. Peritoneal repair and post-surgical adhesion formation. Hum Reprod Update 2001; 7:547-555.

61. DeCherney AH, diZerega GS. Clinical problem of intraperitoneal postsurgical adhesion formation following general surgery and the use of adhesion prevention barriers. Surg Clin N Am 1997; 77:671-688.

62. Seinera P, Arisio R, Decko A, Farina C, Crana F. Laparoscopic myomectomy: indications, surgical technique and complications. Hum Reprod 1997; 12: 1927-1930.

63. Azziz R. Microsurgery alone or with INTERCEED Absorbable Adhesion Barrier for pelvic sidewall adhesion re-formation. The INTERCEED (TC7) Adhesion Barrier Study Group II. Surg Gyncol Obstet 1993; 177:135-139.

64. Khaitan E, Scholz S, Richards William O. Laparoscopic adhesiolysis and placement of Seprafilm: a new technique and novel approach to patients with intractable abdominal pain. J Laparoendosc Adv Surg Tech A 2002; 12: 241-247.

Pagidas K, Tulandi T. Effects of Ringer's lactate, Interceed(TC7) and Gore-Tex Surgical Membrane on postsurgical adhesion formation. Fertil Steril 1992; 57: 199-201.

Verco SJ, Peers EM, Brown CB, Rodgers KE, Roda N, diZerega G. Development of a novel glucose polymer solution (icodextrin) for adhesion prevention: pre-clinical studies. Hum Reprod 2000; 15:1764-1772.

Buckenmaier CC 3rd, Pusateri AE, Harris RA, Hetz SP. Comparison of antiadhesive treatments using an objective rat model. Am Surg 1999; 65:274-282. Buckenmaier CC 3rd, Summers MA, Hetz SP. Effect of the antiadhesive treatments, carboxymethylcellulose combined with recombinant tissue plasmino-gen activator and Seprafilm, on bowel anastomosis in the rat. Am Surg 2000; 66: 1041-1045.

James DC, Ellis H. The effect of streptokinase on the formation of peritoneal adhesions in rats and rabbits. Sangre 1964; 17:192-198 (a preliminary report). James DCO, Ellis H, Hugh TB. The effect of streptokinase on experimental intraperitoneal adhesion formation. J Pathol Bacteriol 1965; 90:279-287. Yagmurlu A, Barlas M, Gursel I, Gokcora IH. Reduction of surgery-induced peritoneal adhesions by continuous release of streptokinase from a drug delivery system. Eur Surg Res 2003; 35:46-49.

Miller JA, Ferguson RL, Powers DL, Burns JW, Shalaby SW. Efficacy of hyaluronic acid/nonsteroidal anti-inflammatory drug systems in preventing postsurgical tendon adhesions. J Biomed Mater Res 1997; 38:25-33.

Montz FJ, Monk BJ, Lacy SM, Fowler JM. Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug: ability to inhibit post-radical pelvic surgery adhesions in a porcine model. Gynecol Oncol 1993; 48:76-79.

Avsar AF, Avsar FM, Sahin M, Topaloglu S, Vatansev H, Belviranli M.

Diphenhydramine and hyaluronic acid derivatives reduce adnexal adhesions and prevent tubal obstructions in rats. Eur J Obstet Gynecol Reprod Biol 2003; 106:

Golan A, Maymon R, Winograd I, Bukovsky I. Prevention of post-surgical adhesion formation using aspirin in a rodent model: a preliminary report. Hum Reprod 1995; 10:1797-1800.

Jackson JK, Skinner KC, Burgess L, Sun T, Hunter WL, Burt HM. Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions. Pharm Res 2002; 19:411-417.

Lebel L. Clearance of hyaluronan from the circulation. Adv Drug Deliv Rev 1991; 7:221 -235.

Crescenzi V, Francescangeli A, Segre AL, Capitani D, Mannina L, Renier D, Bellini D. NMR structural study of hydrogels based on partially deacetylated hyaluronan. Macro Bios 2002; 2:272-279.

Simkovic I, Hricovini M, Soltes L, Mendichi R, Cosentino C. Preparation of water-soluble/insoluble derivatives of hyaluronic acid by cross-linking with epichlorohydrin in aqueous NaOH/NH4OH solution. Carbohydr Pol 1999; 41: 9-14.

Larsen NE, Pollak CT, Reiner K, Leshchiner E, Balazs EA. Hylan gel biomaterial: dermal and immunologic compatibility. J Biomed Mater Res 1993; 27:1129-1134.

81. Larsen NE, Pollak CT, Reiner K, Leshchiner E, Balazs EA. Hylan gel for soft tissue augmentation. Biotechnol BioactPolym 1994:25-33 (Proc Am Chem Soc Symp).

82. Ramamurthi A, Vesely I. Smooth muscle cell adhesion on crosslinked hyaluronan gels. J Biomed Mater Res 2002; 60:196-205.

83. Ramamurthi A, Vesely I. Ultraviolet light-induced modification of crosslinked hyaluronan gels. J Biomed Mater Res 2003; 66A:317-329.

84. Hamburger MI, Lakhanpal S, Mooar PA, Oster D. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum 2003; 32: 296-309.

85. Hammesfahr JFR, Knopf Alan B, Stitik T. Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee. Am J Ortho 2003; 32:277-283.

86. Kahan A, Lleu P-L, Salin L. Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in knee osteoarthritis. Joint Bone Spine 2003; 70:276-281.

87. Karlsson J, Sjoegren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, doubleblind, parallel-design multicenter study. Rheumatology (Oxford, United Kingdom) 2002; 41:1240-1248.

88. Hallen L, Johansson C, Laurent C. Cross-linked hyaluronan (Hylan B gel): a new injectable remedy for treatment of vocal fold insufficiency—an animal study. Acta Otolaryngol 1999; 119:107-111.

89. Crescenzi V, Francescangeli A, Capitani D, Mannina L, Renier D, Bellini D. Hyaluronan networking via Ugi's condensation using lysine as cross-linker diamine. Carbohydr Polym 2003; 53:311-316.

90. Vercruysse KP, Marecak DM, Marecek JF, Prestwich GD. Synthesis and in vitro degradation of New polyvalent hydrazide cross-linked hydrogels of hyaluronic acid. Bioconj Chem 1997; 8:686-694.

91. Prestwich GD, Marecak DM, Marecek JF, Vercruysse KP, Ziebell MR. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J Control Release 1998; 53:93-103.

92. Shu XZ, Liu Y, Palumbo F, Prestwich GD. Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials 2003; 24:3825-3834.

93. Huang WJ, Johns DB, Kronenthal RL. US patent #5532221.

94. Johns DB, Keyport GM, Hoehler F, diZerega GS. Reduction of postsurgical adhesions with Intergel adhesion prevention solution: a multicenter study of safety and efficacy after conservative gynecologic surgery. Fertil Steril 2001; 76: 595-604.

95. Thornton MH, Johns DB, Campeau JD, Hoehler F, Dizerega GS. Clinical evaluation of 0.5% ferric hyaluronate adhesion prevention gel for the reduction of adhesions following peritoneal cavity surgery: open-label pilot study. Hum Reprod 1998; 13:1480-1485.

96. Lundorff P, van Geldorp H, Tronstad SE, Lalos O, Larsson B, Johns DB, diZerega GS. Reduction of post-surgical adhesions with ferric hyaluronate gel: a European study. Hum Reprod 2001; 16:1982-1988.

97. http://www.lifecore.com/products/Ha_division.asp.

98. Kocak I, Unlu C, Akcan Y, Yakin K. Reduction of adhesion formation with cross-linked hyaluronic acid after peritoneal surgery in rats. Fertil Steril 1999; 72: 873-878.

Belluco C, Meggiolaro F, Pressato D, Pavesio A, Bigon E, Dona M, Forlin M, Nitti D, Lise M. Prevention of postsurgical adhesions with an autocrosslinked hyaluronan derivative gel. J Surg Res 2001; 100:217-221. Acunzo G, Guida M, Pellicano M, Tommaselli GA, Sardo ADS, Bifulco G, Cirillo D, Taylor A, Nappi C. Effectiveness of auto-cross-linked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic adhesiolysis: a prospective, randomized, controlled study. Hum Reprod 2003; 18:1918-1921. Burns JW, Cox S, Walts AE. US patent #5017229.

Kuo JW, Swann DA, Prestwich GD. Chemical modification of hyaluronic acid by carbodiimides. Bioconj Chem 1991; 2:232-241.

Hamilton R, Fox EM, Acharya RA, Walts AE. US patent #4,937,270.

Pouyani T, Kuo JW, Harbison GS, Prestwich GD. Solid-state NMR of N-acylureas derived from the reaction of hyaluronic acid with isotopically-labeled carbodii-

mides. J Am Chem Soc 1992; 114:5972-5976.

Beck DE. The role of Seprafilm bioresorbable membrane in adhesion prevention. Eur J Surg Suppl 1997:49-55.

Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group. Fertil Steril 1996; 66:904-910. Beck DE, Cohen Z, Fleshman JW, Kaufman HS, van Goor H, Wolff BG. A prospective, randomized, multicenter, controlled study of the safety of seprafilm adhesion barrier in abdominopelvic surgery of the intestine. Dis Colon Rectum 2003; 46:1310-1319.

Tzianabos AO, Cisneros RL, Gershkovich J, Johnson J, Miller RJ, Burns JW, Onderdonk AB. Effect of surgical adhesion reduction devices on the propagation of experimental intra-abdominal infection. Arch Surg 1999; 134:1254-1259. Baptista ML, Bonsack ME, Delaney JP. Seprafilm reduces adhesions to polypropylene mesh. Surgery 2000; 128:86-92. Greenawalt K, Gershkovich J. US patent #6,056,970.

Greenawalt KE, Butler TJ, Rowe EA, Finneral AC, Garlick DS, Burns JW. Evaluation of Sepramesh biosurgical composite in a rabbit hernia repair model. J Surg Res 2000; 94:92-98.

Kimmelman CP, Edelstein DR, Cheng HJ. Sepragel sinus (hylan B) as a postsurgical dressing for endoscopic sinus surgery. Otolaryngol Head Neck Surg 2001; 125:603-608.

Catalano PJ, Roffman EJ. Evaluation of middle meatal stenting after minimally invasive sinus techniques (MIST). Otolaryngol Head Neck Surg 2003; 128: 875-881.

ANG.gerup, US patent #5,827,937.

Narins Rhoda S, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29:588-595.

Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and non-animal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29:802-809.

117. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998; 24:1317-1325.

118. Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconj Chem 1999; 10:755-763.

119. Pouyani T, Prestwich GD. Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials. Bioconj Chem 1994; 5: 339-347.

120. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000; 1:208-218.

121. Della VF, Romeo A. Eur patent application, #216453.

122. Goei L, Topp E, Stella V, Benedetti L, Biviano F, Callegaro L. Drug release from hydrocortisone esters of hyaluronic acid: influence of ester hydrolysis rate on release rate. Polym Med 1992:85-92.

123. Goei L, Topp E, Stella V, Benedetti L, Biviano F, Callegaro L. Polymeric prodrugs: recent experience with devices formed from steroid esters of hyaluronic acid. Polym Med 1992:93-101.

124. Rajewski LG, Stinnett AA, Stella VJ, Topp EM. Enzymic and nonenzymic hydrolysis of a polymeric prodrug: hydrocortisone esters of hyaluronic acid. Int J Pharm 1992; 82:205-213.

125. Cheung YW, Po ALW, Irwin WJ. Resistance to enzymic hydrolysis as a parameter in drug potency. Int J Pharm 1985; 27:325-333.

126. Payan E, Jouzeau JY, Lapicque F, Bordji K, Simon G, Gillet P, O'Regan M, Netter P. In vitro drug release from HYC 141, a corticosteroid ester of high molecular weight hyaluronan. J Control Release 1995; 34:145-153.

127. Barbucci R, Magnani A, Baszkin A, Da Costa ML, Bauser H, Hellwig G, Martuscelli E, Cimmino S. Physicochemical surface characterization of hyaluronic acid derivatives as a new class of biomaterials. J Biomater Sci Polym Ed 1993; 4:245-273.

128. Milella E, Brescia E, Massaro C, Ramires PA, Miglietta MR, Fiori V, Aversa P. Physico-chemical properties and degradability of non-woven hyaluronan benzylic esters as tissue engineering scaffolds. Biomaterials 2001; 23: 1053-1063.

129. Campoccia D, Hunt JA, Doherty PJ, Zhong SP, O'Regan M, Benedetti L, Williams DF. Quantitative assessment of the tissue response to films of hyaluronan derivatives. Biomaterials 1996; 17:963-975.

130. Benedetti L, Cortivo R, Berti T, Berti A, Pea F, Mazzo M, Moras M, Abatangelo G. Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomaterials 1993; 14:1154-1160.

131. Aigner J, Tegeler J, Hutzler P, Campoccia D, Pavesio A, Hammer C, Kastenbauer E, Naumann A. Cartilage tissue engineering with novel nonwoven structured biomaterial based on hyaluronic acid benzyl ester. J Biomed Mater Res 1998; 42: 172-181.

132. Brun P, Abatangelo G, Radice M, Zacchi V, Guidolin D, Daga Gordini D, Cortivo R. Chondrocyte aggregation and reorganization into three-dimensional scaffolds. J Biomed Mater Res 1999; 46:337-346.

133. Tonello C, Zavan B, Cortivo R, Brun P, Panfilo S, Abatangelo G. In vitro reconstruction of human dermal equivalent enriched with endothelial cells. Biomaterials 2003; 24:1205-1211.

134. Grigolo B, Roseti L, Fiorini M, Fini M, Giavaresi G, Nicoli Aldini N, Giardino R, Facchini A. Transplantation of chondrocytes seeded on a hyaluronan derivative (Hyaff-11) into cartilage defects in rabbits. Biomaterials 2001; 22:2417-2424.

135. Solchaga LA, Yoo JU, Lundberg M, Dennis JE, Huibregtse BA, Goldberg VM, Caplan AI. Hyaluronan-based polymers in the treatment of osteochondral defects. J Orthop Res 2000; 18:773-780.

136. Pavesio A, Abatangelo G, Borrione A, Brocchetta D, Hollander Anthony P, Kon E, Torasso F, Zanasi S, Marcacci M. Hyaluronan-based scaffolds (Hyalograft C) in the treatment of knee cartilage defects: preliminary clinical findings. Novartis Found Symp 2003; 249:203-217 (discussion 229-233, 234-208, 239-241).

137. Lisignoli G, Zini N, Remiddi G, Piacentini A, Puggioli A, Trimarchi C, Fini M, Maraldi NM, Facchini A. Basic fibroblast growth factor enhances in vitro mineralization of rat bone marrow stromal cells grown on nonwoven hyaluronic acid based polymer scaffold. Biomaterials 2001; 22:2095-2105.

138. Ambrosio L, Borzacchiello A, Netti PA, Nicolais L. Properties of new materials: rheological study on hyaluronic acid and its derivative solutions. J Macromol Sci Pure Appl Chem 1999; A36:991-1000.

Chemistry and Biology of Hyaluronan H.G. Garg and C.A. Hales (editors) © 2004 Elsevier Ltd. All rights reserved.



Thank you for deciding to learn more about the disorder, Osteoarthritis. Inside these pages, you will learn what it is, who is most at risk for developing it, what causes it, and some treatment plans to help those that do have it feel better. While there is no definitive “cure” for Osteoarthritis, there are ways in which individuals can improve their quality of life and change the discomfort level to one that can be tolerated on a daily basis.

Get My Free Ebook

Post a comment